GlobeNewswire Inc.··NaBiomea Fusion Advances Diabetes Drug With Two Phase II Studies as Treatment Gap Widens
Biomea Fusion initiates two Phase II trials of icovamenib for type 2 diabetes patients failing standard therapies, building on earlier positive data showing durable HbA1c reductions.
BMEAType 2 diabetesicovamenib